The intricate interaction between all the components of BC TME requires the development of a targeted therapy that would inhibit or reduce the expression of the immunoinhibitory receptors such as PD-1/PD-L1, CTLA-4 and TNFR2, which control and regulate various signaling pathways. The gene discussed is CTLA4; the disease is breast cancer.